Table 2 Salmonella isolates susceptible, intermediate and resistant to various antibiotics.
Class/group of antibiotics | Antibiotics | Abbreviation | Disc potency (μg) | Susceptible (%) | Intermediate (%) | Resistant (%) |
|---|---|---|---|---|---|---|
Penicillin | Ampicillin | AMP | 10 | 20 (40) | 0 | 37 (64.91) |
Cephalosporin | Cefepime | FEP | 30 | 01 (1.75) | 0 | 56 (98.24) |
Ceftriaxone | CRO | 30 | 18 (31.57) | 17 (29.82) | 22 (38.59) | |
Ceftazidime | CZ | 30 | 0 | 32 (56.14) | 25 (43.85) | |
Carbapenems | Imipenem | IMP | 10 | 08 (14.03) | 21 (36.84) | 28 (49.12) |
Meropenem | MEM | 10 | 43 (75.43) | 13 (22.80) | 01 (1.75) | |
Lipopeptides | Colistin | CT | 10 | 03 (5.26) | 0 | 54 (94.73) |
Polymyxin B | PB | 300U | 09 (15.78) | 0 | 48 (84.21) | |
Aminoglycosides | Gentamicin | CN | 10 | 29 (50.87) | 08 (14.03) | 20 (35.08) |
Tobramycin | TOB | 10 | 33 (57.89) | 13 (22.80) | 11 (19.29) | |
Amikacin | AK | 30 | 42 (73.68) | 01 (1.75) | 14 (24.56) | |
Kanamycin | K | 30 | 10 (17.54) | 02 (3.50) | 45 (78.94) | |
Streptomycin | S | 10 | 07 (12.28) | 09 (15.78) | 41 (71.92) | |
Macrolides | Azithromycin | AZM | 15 | 04 (7.01) | 0 | 53 (92.98) |
Erythromycin | E | 15 | 0 | 0 | 57 (100) | |
Tetracyclines | Tetracycline | TET | 30 | 04 (7.01) | 03 (5.26) | 50 (87.71) |
Quinolones and fluoroquinolones | Ciprofloxacin | CIP | 05 | 01 (1.75) | 08 (14.03) | 48 (84.21) |
Levofloxacin | LEV | 05 | 04 (7.01) | 38 (66.66) | 15 (26.31) | |
Nalidixic Acid | NA | 30 | 05 (8.77) | 06 (10.52) | 46 (80.70) | |
Folate pathway antagonists | Sulfamethoxazole-Trimethoprim | SXT | 1.25/23.75 | 09 (15.78) | 02 (3.50) | 46 (80.70) |
Phenicols | Chloramphenicol | C | 30 | 08 (14.03) | 05 (8.77) | 44 (77.19) |
